- ASSISTANT PROFESSOR Medicine, Liver Diseases
Ph.D., University of Tokyo
M.D., University of Tsukuba
Postdoc, Broad Institute of MIT and Harvard
Hoshida laboratory (website available soon)Hoshida lab employs multidisciplinary, translational approaches to chronic liver diseases including liver cirrhosis and cancer, with particular emphasis on genomics, biostatistics, bioinformatics, clinical diagnostics, and chemical biology, and is currently focusing on the following projects with NIH support.
1. Molecular classification and prognostic biomarkers in liver cirrhosis and cancer
Liver cancer is the fastest and only increasing cancer mortality in the U.S. with still dismal prognosis (5-yr survival <12%). Liver cirrhosis is the major cause of liver cancer. Therefore, regular cancer surveillance is offered once cirrhosis is diagnosed. However, cirrhosis is extremely prevalent (1~2% of population), and as a consequence, >80% of liver cancer patients are diagnosed at late stage without receiving proper cancer surveillance. Thus, molecular prognostic biomarkers would greatly help clinical management of the patients by identifying those who really need the cancer surveillance and therapies that preventive cancer development and poor prognosis. In addition, molecular classification of liver cancer tumors will greatly inform more personalized treatment decision. To achieve these goals, we perform genomic profiling of patient specimens, explore molecular classification and prognostic biomarkers by utilizing biostatistics and bioinformatics methodologies, develop data analysis algorithms and software, develop clinically applicable assay platforms, and develop informatics resources for in silico prognostic biomarker and therapeutic target analysis.
2. Cancer-preventive therapies in liver cirrhosis
Liver cirrhosis is an extremely high-risk condition to develop cancer (~5% every year), and therefore the best target of cancer preventive therapies. However, no such therapy has been established yet. For cancer preventive target discovery, we employ bioinformatics, systems biology approaches to genomic profiles of liver cirrhosis patients, cell lines, and variety of animal models. Candidate targets are verified in animal models and patient tissues, and prioritized for subsequent clinical trials. To enable more effective and less toxic cancer preventive therapies, we are developing nanotechnology-based drug delivery system to concentrate molecular targeted agents in target cell type in the liver.
- Research positions
Postdoc fellow in Bioinformatics
We are seeking a highly qualified Bioinformatics expert with software engineering skills to develop and implement bioinformatics/biostatistics methodologies for clinical outcome prediction, disease classification, and therapeutic target discovery by using large-scale genomics data such as microarray and sequencing. Successful candidate will closely interact with experienced bioinformatics, biostatistics, andsoftware engineering experts at the Institute of Genomics and Multiscale Biology.
- Highly motivated PhD in Statistics, Computer Science, Bioinformatics, or other relevant areas.
- Significant familiarity with standard machine learning and statistical modeling algorithms.
- Strong programing skills with a statistical computing language preferably R.
- Experience of high-throughput genomic data analysis.
- Strong software engineering skills and experience (Java, SQL, web application).
- Quick learner of new technologies and analysis algorithms.
- Strong interpersonal skills and a track record of collaborative work in multidisciplinary research environment.
To apply, e-mail a CV, a cover letter, URL of web application or database (if any), and contact information of 3 references to:
Yujin Hoshida, MD, PhD (email@example.com)
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. The New England journal of medicine 2008 Nov; 359(19): 1995-2004.
Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013 May; 144(5): 1024-30.
Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer research 2009 Sep; 69(18): 7385-92.
Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Lin28 promotes transformation and is associated with advanced human malignancies. Nature genetics 2009 Jul; 41(7): 843-8.
Hoshida Y, Fuchs BC, Tanabe KK. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges [review]. Current cancer drug targets 2012 Nov; 12(9): 1129-59.
Hoshida Y. Molecular epidemiology of hepatocellular carcinoma. Clinical Liver Disease: an official learning resource of American Association for the Study of Liver Diseases 2012 1(6):177-9.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Hoshida did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Hess Center for Science and Medicine; Tisch Cancer Institute
1470 Madison Ave, Box 1123
New York, NY 10029